By WEforum Editors
For decades, women have whispered about it: mood shifts, brain fog, sudden anxiety, disrupted sleep, unexplained weight changes, joint aches, migraines, and the persistent sense that something is “off,” even when laboratory results return within normal ranges.
Perimenopause. Menopause. Hormones.
Yet for something nearly universal, the science behind it is surprisingly young.
Some women move through this transition with minimal disruption. Others experience a period of profound physiological and emotional instability. Both experiences are valid. The variation is not a failure of resilience, nor is it exaggeration. It reflects biology.
If you are entering perimenopause, menopause, or postmenopause for the first time, you are stepping into a distinct neuroendocrine stage of life. While some women feel fully informed and confident in decisions they have already made, many are navigating this terrain without a clear map. Staying informed, understanding evolving research, and keeping current with evidence is not optional. It is essential to maintain agency in a healthcare landscape that is still evolving.
Why We Are Still Catching Up
Perimenopause and menopause are universal biological transitions in the lives of people assigned female at birth. Yet despite the fact that virtually all women live through these stages, medical research and clinical understanding of them are only now catching up. Many women report symptoms, from hot flashes and sleep disturbances to mood shifts and metabolic changes, only to find that clinicians, research summaries, and even textbooks offer partial or conflicting explanations.
This gap exists for several reasons.
Every woman experiences this differently. And yet, for most of modern medical history, we didn’t study women long enough, or carefully enough, to understand why. It’s not that women’s health was ignored entirely. But it was underfunded, understudied, and often generalized from research done primarily on men.
Until 1993, women were not routinely required to be included in federally funded clinical research in the United States.¹ That changed with the National Institutes of Health Revitalization Act of 1993, which mandated inclusion of women and minorities in NIH-funded trials. While this legislation significantly improved representation, careful analysis of how treatments affect women differently is still relatively recent.
The implications are substantial. Modern clinical research expanded dramatically in the twentieth century, yet consistent inclusion of women in study design and analysis spans just over three decades. That helps explain why many women today feel they are navigating perimenopause and menopause without a clear map grounded in evidence.
Cardiovascular disease, oncology, and metabolic disorders have been studied extensively for decades. By contrast, focused research into the midlife female hormonal transition has accelerated primarily in the past 10–15 years, particularly in areas such as brain health, metabolic regulation, and cardiovascular timing patterns.²
Several factors contributed to this delay. Female hormonal patterns are cyclical and dynamic, which makes study design and long-term outcomes harder to study. The early findings of the Women’s Health Initiative in 2002 raised concerns about combined estrogen–progestin therapy and its association with breast cancer and cardiovascular events.³ Subsequent analyses clarified that risks varied significantly by age, timing of initiation, and formulation, but the initial interpretation led to a substantial decline in hormone therapy use. In addition, clinical care remains siloed: gynecology, endocrinology, psychiatry, and cardiology frequently operate independently, even though hormonal transitions intersect all of these domains.
None of this reflects neglect of women’s health. It reflects complexity. But complexity without coordination leaves many women feeling unsupported.
Why Hormonal Research Is So Complex
There are several reasons, and none of them are simple.
1. Hormones are cyclical and complex.
Unlike male hormonal patterns, female hormones fluctuate monthly for decades before shifting dramatically during perimenopause. This makes the study design more complicated and more expensive.
2. Fear from earlier hormone research.
The early 2000s Women’s Health Initiative (WHI) study raised concerns about hormone replacement therapy (HRT), particularly regarding breast cancer and cardiovascular risk. Later analyses revealed nuance, including differences based on age, timing, formulation, and individual risk factors. The initial headlines led to a dramatic reduction in HRT use. Many clinicians pulled back entirely. The conversation stalled.
3. Cultural silence.
Menopause was framed as something to endure quietly, not investigate rigorously. Symptoms were often dismissed as stress, aging, or psychological issues.
4. Fragmented care.
Endocrinology, gynecology, psychiatry, cardiology: Hormones sit at the intersection of many specialties. Yet few systems treat women’s hormonal transitions holistically.
Every Woman Is Different
Perimenopause can begin in the late 30s or 40s and may last several years. Some women experience hot flashes, while others report panic attacks, insomnia, joint pain, migraines, or sudden shifts in mood. Some barely notice the transition at all. Large cohort studies show wide differences in symptom severity, duration, and overall experience.¹² Genetics, stress history, trauma exposure, cardiometabolic health, nutrition, sleep quality, environmental exposures, and individual biology all play a role.
There is no universal template for this transition. That variability can become a burden in itself, particularly when answers are not clear-cut. When explanations are incomplete or guidance
varies widely, many women find themselves searching, sometimes exhaustively, for explanations and solutions that feel fragmented, inconsistent, or simply unavailable.
At the same time, a common thread runs through many of these experiences. What one woman encounters may look very different from what her sister, mother, or close friend experiences. The widely recognized “hot flash” narrative captures only part of the picture, and standardized advice does not work for everyone. Too often, menopause has been reduced to a cultural caricature rather than treated as the complex biological transition it is.
What Is Actually Happening Biologically
Perimenopause is not merely the winding down of menstrual cycles. It represents a coordinated neuroendocrine shift, meaning changes in the way the brain and hormone-producing glands communicate, involving systems such as the hypothalamus, pituitary gland, ovaries, adrenal system, and peripheral tissues.
A. The Neuroendocrine Shift
Estrogen receptors are found throughout the brain, including areas involved in memory, decision-making, and hormone regulation such as the hippocampus, prefrontal cortex, and hypothalamus.⁴ As estrogen levels fluctuate and eventually decline, brain signaling systems involving serotonin, dopamine, and norepinephrine can also be affected.⁴,⁵
This helps explain why some women experience:
Increased anxiety
Mood lability
Sleep disruption
Cognitive complaints such as difficulty finding words or concentrating
Research suggests that while long-term dementia risk depends on many factors, short-term cognitive complaints during perimenopause are common and often reversible.⁴ Scientists are still working to understand exactly why this happens.
B. Sleep Architecture
Vasomotor symptoms such as hot flashes can disrupt sleep, but hormonal changes may also influence sleep architecture directly through thermoregulatory and neurochemical pathways.⁶ Chronic sleep disruption, in turn, affects metabolism and mood, creating a cycle that can reinforce itself.
C. The Metabolic Transition
Midlife hormonal shifts are associated with changes in body composition, including increased abdominal fat and reduced lean muscle mass.⁷ Estrogen plays a role in glucose regulation and lipid metabolism. As levels decline, LDL cholesterol often rises, and insulin sensitivity may change.⁷,⁸
These shifts do not occur in every woman, and lifestyle factors exert a powerful influence. But the transition window appears to represent a period of metabolic adjustment that deserves attention rather than dismissal.
D. Cardiovascular Timing
Cardiovascular disease risk accelerates after menopause.⁸ The “timing hypothesis” suggests that initiation of menopausal hormone therapy closer to the onset of menopause may have different effects on heart health than starting HRT many years later.⁹
The nuance matters. Age, vascular health, formulation, and how the hormone is delivered can all influence outcomes. This is why blanket statements, either pro- or anti-hormone therapy, are misleading.
E. Bone and Musculoskeletal Health
Estrogen helps slow the natural breakdown of bone. As levels decline, bone loss can speed up, increasing fracture risk over time.¹⁰ Muscle mass and strength may also decline during midlife, which highlights the importance of resistance training and adequate protein intake.
F. Immune and Inflammatory Regulation
Sex hormones affect how the immune system communicates and responds. Emerging evidence suggests that menopause may influence inflammation and immune balance, though scientists are still studying the causes and health implications.¹¹ This is an area of active research, particularly regarding autoimmune conditions, but firm conclusions have not yet been reached.
Hormone Therapy: Evidence, Not Fear
Menopausal hormone therapy (MHT), which includes estrogen with or without progestogen, remains the most effective treatment for moderate-to-severe hot flashes and night sweats.³,¹³ It also prevents bone loss and reduces fracture risk while in use.¹³
Risk profiles depend on:
- Age at initiation
- Time since menopause
- Personal cardiovascular risk
- Breast cancer history
- Route of administration (oral vs transdermal)
The 2022 Position Statement of the North American Menopause Society emphasizes individualized evaluation and shared decision-making rather than avoiding hormone therapy altogether.¹³
At the same time, hormone therapy is not a universal solution. Long-term individualized risk profiles require continued study.
Balanced counseling is essential.
What We Know and What We Do Not Yet Know
We know that:
- Estrogen, progesterone, and testosterone all decline or fluctuate in midlife.
- These shifts extend beyond reproduction, affecting the brain, heart, skeletal system, metabolic pathways, and immune regulation.⁴,⁷ Emerging research suggests hormonal changes may influence inflammation and autoimmune conditions, though scientists are still working to understand how this happens and what it may mean long term.
- Timing appears to matter when considering hormone therapy (earlier intervention may carry different risks and benefits than later).⁹
- Lifestyle interventions (sleep, resistance training, nutrition, stress management) significantly influence outcomes across these systems.¹⁴
We do not yet fully understand:
- Why do some women have severe symptoms, and others do not?
- The long-term, individualized risk-benefit profiles of different hormone formulations across diverse populations.13
- The exact reasons estrogen changes are linked to mood disorders and cognitive symptoms.⁵
- How environmental exposures interact with endocrine function.
- Optimal strategies for personalized care tailored to different populations and health backgrounds.
- The full interaction between hormone-disrupting chemicals and midlife hormonal shifts.¹⁵
The science surrounding menopause is still evolving. Some claims circulating online are supported by strong evidence; others are based on early findings or incomplete data. Our goal is to distinguish clearly between what research shows with confidence, what remains under active investigation, and where genuine uncertainty still exists.
Why This Series Matters
Even with growing research, important questions remain. We still do not fully understand why some women experience severe symptoms while others do not, how hormonal changes influence brain health over time or how environmental and genetic factors interact with endocrine changes across midlife. Early studies suggest connections between menopause symptom burden and cognitive patterns, but these findings remain preliminary and require further research.
Women now spend approximately one-third of their lives in postmenopause.¹⁶ This stage of life is therefore not a narrow gynecologic issue. It is a neurological, metabolic, cardiovascular, skeletal, immunologic, and public health issue.
Hormones influence how women sleep, think, metabolize energy, maintain bone integrity, regulate mood, experience intimacy, and manage long-term disease risk. They also shape how women show up in families, workplaces, and communities.
This series will explore:
- Hormone physiology in accessible but rigorous terms
- Brain health and cognitive research
- Metabolic transitions and insulin regulation
- Cardiovascular timing and risk modification
- Evidence behind hormone therapy
- Lifestyle interventions supported by data
- Controversial claims and how to evaluate them
Because every woman’s hormonal journey is unique and shaped by her biology, lifestyle, health history, and environment, a thoughtful, evidence-based approach is essential.
Every article in this series will distinguish carefully between established evidence, emerging research, and speculation. The goal is not to create alarm or false certainty, but to provide clarity in a field that is still developing.
The midlife hormonal transition is complex, and the science surrounding it continues to evolve. Complexity, however, should not prevent understanding. Women deserve clear, rigorous information about what is happening in their bodies and how best to navigate the decades that follow.
This article is intended for educational purposes only and does not constitute medical advice. Readers should consult their physician or a qualified healthcare professional regarding any questions about their health or treatment decisions.
References
- NIH Revitalization Act of 1993. Public Law 103-43.
- Mauvais-Jarvis F et al. Sex and gender in endocrine research. Nat Rev Endocrinol. 2020.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
- Maki PM et al. Menopause and brain health. Nat Rev Neurol. 2021.
- Soares CN. Depression in peri- and postmenopausal women. Lancet Psychiatry. 2019.
- Freedman RR. Menopause, thermoregulation and sleep. Sleep Med Rev. 2020.
- El Khoudary SR et al. Menopause transition and cardiometabolic risk. Circulation. 2020.
- Matthews KA et al. Lipid changes during menopause. J Clin Endocrinol Metab. 2022.
- Hodis HN, Mack WJ. Timing hypothesis revisited. J Am Coll Cardiol. 2021.
- Daly RM et al. Exercise and bone health in menopause. J Clin Endocrinol Metab. 2021.
- Kovats S. Estrogen and immune regulation. Nat Rev Immunol. 2020.
- Santoro N et al. Symptom variability during perimenopause. Menopause. 2021.
- The 2022 Position Statement of The North American Menopause Society. Menopause. 2022.
- Piercy KL et al. Physical activity guidelines and metabolic health. Med Sci Sports Exerc. 2018.
- Gore AC et al. Endocrine-disrupting chemicals review. Endocr Rev. 2019.
- United Nations World Population Prospects 2022.
